Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Tenaya Therapeutics, Inc. (TNYA)

Sector - Healthcare

Price chart

+34.73%
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Their vision is to change the treatment paradigm for heart disease, the leading cause of death in the world, and in doing so improve and extend the lives of millions of individuals and families. They are advancing a pipeline of disease-modifying therapies developed using their product platforms and core internal capabilities to target defined sub-populations of patients with both rare and highly prevalent forms of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and University of Texas Southwestern Medical Center (UTSW), they are developing therapies through scientific advancements in three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. While their Gene Therapy and Cellular Regeneration platforms focus on the use of viral vectors for drug delivery, their Precision Medicine platform enables them to identify promising targets and product candidates in a modality-agnostic manner, including gene therapies, small molecules, and biologics.
Industry
Pharmaceutical Preparations
CEO CFO
Faraz Ali Leone D. Patterson
Employees Founded
85 2016

Contacts

Address: 171 Oyster Point Boulevard, 5th Floor South San Francisco, Ca 94080

Telephone: (650) 825-6990

Web page: http://www.tenayatherapeutics.com

IPO information

First Trade Date 7/30/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 10
Shares Revised (MM) 12
Expected offer amount (MM) $150
Realized offer amount(MM) $180

Financial Data (last reporting year)

Market Cap (MM) $559.8
Revenues (MM) $0
Net Income (Loss) (MM) $-42.45

Voting

What do you think will happen with the TNYA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ Cowen/ Piper Sandler
CO-Managers
Chardan

Sector: Healthcare

Tweets about $TNYA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats